KDD68904
Colorimetric
Plasma, Serum
Quantitative
78.125 - 5,000 ng/mL
33.12 ng/mL
CV<20%
80-120%
2-8 ℃
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
CHIR-12,12,HCD122, CAS: 903512-50-5
Inhibition of GSK-3β activity suppresses HCC malignant phenotype by inhibiting glycolysis via activating AMPK/mTOR signaling., PMID:31404613
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4)., PMID:29572070
Emerging immune targets for the treatment of multiple myeloma., PMID:29421983
Emerging antibodies for the treatment of multiple myeloma., PMID:27195659
Activity of the CD40 antagonistic antibody lucatumumab - insights from CLL-niche mimicking xenografts and fludarabine combinations., PMID:26758550
Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art., PMID:25249370
Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials., PMID:24555495
Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma., PMID:24219359
A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma., PMID:22861192
Interfering with CD40 ligation: a sensitive matter in chronic lymphocytic leukemia., PMID:22563816
Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia., PMID:22475052
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
